UK drug giants in the spotlight as part of latest sector review

Berenberg's latest pharmaceutical sector review recommends selective 'buy' opportunities, highlighting AstraZeneca with a 24% upside due to its strong pipeline and R&D returns, while assigning GSK a 'hold' for limited growth despite its dividend. The report also favors AbbVie and Sanofi for successful portfolio transitions and strength, alongside Novo Nordisk's obesity market leadership, contrasting with 'hold' ratings for fully priced Eli Lilly and other major peers. Despite historically low sector valuations, largely attributed to political risk, improving R&D returns and substantial industry cash reserves underscore the importance of discerning stock selection for investors.

Analysis

A recent Berenberg review of the pharmaceutical sector underscores a significant divergence in prospects among major players, advocating for a highly selective investment approach. Despite the sector trading at a historically low valuation of approximately 12.5 times 2026 earnings—a discount largely driven by political risks such as US drug pricing reforms—underlying fundamentals show improvement. Notably, R&D returns are strengthening, with the 'class of 2020' pipeline delivering a 14% return, well above the 8% initially forecast. AstraZeneca (AZN) is highlighted as a 'buy' with a £142 price target, implying 24% upside, driven by high single-digit sales growth, a robust oncology and immunology pipeline, and a management team with a strong track record of R&D execution. Conversely, GSK is rated 'hold' with a marginal 8% upside to its £16 target; while it offers a 4% dividend yield, it is seen as a 'plodder' with limited pipeline depth and financial firepower. Other 'buy' ratings include AbbVie, for successfully managing the transition from its blockbuster Humira, and Sanofi, for its durable portfolio led by Dupixent. In contrast, momentum names like Eli Lilly are now considered 'hold', with its 400% five-year share price increase suggesting the obesity market opportunity is fully priced in. This bifurcation is further evidenced by the sector's uneven five-year total shareholder returns, reinforcing the thesis that stock selection is critical.

Key Decisions for Investors

• Given the wide dispersion in company outlooks, prioritize a stock-picking strategy over broad sector exposure, focusing on firms with superior R&D productivity and clear growth catalysts.
• For growth-oriented portfolios, consider overweighting names like AstraZeneca and AbbVie, which demonstrate strong pipeline momentum and have received favorable analyst ratings with significant price target upside.
• Investors seeking income could consider GSK for its 4% dividend yield, but must be prepared for limited capital appreciation and a less dynamic growth profile compared to its peers.
• Exercise caution on stocks with recent parabolic runs such as Eli Lilly, as the market may have already priced in future growth, limiting near-term alpha potential.
• Monitor US political developments related to drug pricing, as this remains the primary overhang on sector valuations and a key risk factor that could impact sentiment and multiples across the industry.